CLAIMS

1. A compound of formula (I)



(I)

wherein ring A and ring B each independently represents a cyclic group which may have a substituent(s);

K, Q and M each independently represents a bond or a spacer having from 1 to 8 atoms in its principle chain;

ring D and ring E each independently represents a cyclic group which may have a substituent(s);

L represents a bond, or a spacer having from 1 to 3 atoms in its principle chain;

Z represents an acidic group which may be protected; and

t represents 0 or 1, or

a salt thereof, a solvate thereof or a prodrug thereof.

2. The compound according to claim 1, wherein the compound of formula (I) is an optically active compound of formula (I-A):



(I-A)

wherein  represents β-configuration; and other symbols have the same meanings as described in claim 1.

3. The compound according to claim 1, wherein ring A is a benzene ring which may have a substituent(s).

4. The compound according to claim 1, wherein K is C1-4 alkylene which may be substituted.

5. The compound according to claim 1, wherein ring B is an indane ring which may have a substituent(s).

6. The compound according to claim 1, wherein Q is methylene which may be substituted or ethylene which may be substituted.

7. The compound according to claim 1, wherein ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s).

8. The compound according to claim 1, wherein Z is -COOH; $-CONHSO_2R^1$, in which R^1 represents an aliphatic hydrocarbon group which may be substituted or a cyclic group which may have a substituent(s); or tetrazolyl.

9. The compound according to claim 1, wherein



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted.

10. The compound according to claim 1,

wherein ring A is a benzene ring which may have a substituent(s);

ring B is an indane ring which may have a substituent(s);

ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s);



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted; and

Z is -COOH; $-CONHSO_2R^1$, in which R^1 is an aliphatic hydrocarbon group which may be substituted or a cyclic group which may have a substituted, or tetrazolyl.

11. The compound according to claim 1, which is selected from the group consisting of:

(1) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,

(2) (1-{(2S)-2-[(S)-(3,5-dimethoxy-4-methylphenyl)(hydroxy)methyl]-5-thien-3-ylpentyl}-1H-pyrrol-3-yl)acetic acid,

(3) {1-[(2S,3S)-2-(1,3-benzodioxol-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,

(4) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}acetic acid,

(5) {1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,

(6) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,

(7) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,

(8) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}propanoic acid,

(9) 3-{1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,

(10) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,

(11) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-N-(methylsulfonyl)acetamide,

(12) [1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-4-(methoxylcarbonyl)-1H-pyrrol-3-yl]acetic acid,

(13) N-(3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoyl)-2-methylbenzenesulfonamide,

(14) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acrylic acid,
(15) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrol-3-yl}-2-methylpropanoic acid, and
(16) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-2-methylacrylic acid.

12. A pharmaceutical composition comprising the compound of formula (I) according to claim 1, a salt thereof, a solvate thereof or a prodrug thereof.

13. The pharmaceutical composition according to claim 12, which is an LPA receptor antagonist.

14. The pharmaceutical composition according to claim 13, wherein the LPA receptor is EDG-2.

15. The pharmaceutical composition according to claim 12, which is an agent for prevention and/or treatment for urinary system disease, carcinoma-associated disease, proliferative disease, inflammation/immune system disease, disease caused by secretory dysfunction, brain-related disease or chronic disease.

16. A method for prevention and/or treatment of EDG-2 related diseases, which comprises administering to a mammal an effective amount of the compound of formula (I) according to claim 1, a salt thereof, a solvate thereof or a prodrug thereof.

17. Use of the compound of formula (I) according to claim 1, a salt thereof, a solvate thereof or a prodrug thereof for the manufacture of an agent for prevention and/or treatment of EDG-2 related diseases.

18. A pharmaceutical composition comprising a combination of the compound of formula (I) according to claim 1, a salt thereof, a solvate thereof or a prodrug thereof with at least one agent selected from an LPA receptor antagonist, an α1 blocking agent, an anticholinergic agent, a 5α-reductase inhibitor and an anti-androgenic agent.